Herpesvirus Pharmacology

Acyclovir remains the prototype antiviral against which all herpesvirus agents are compared. Its selectivity for virus-infected cells rests on a two-step activation mechanism that concentrates the active drug precisely where it is needed, leaving uninfected host cells essentially unexposed to inhibitory concentrations.

Acyclovir is an acyclic nucleoside analogue of guanosine. Its selectivity depends on preferential phosphorylation by virus-encoded thymidine kinase (TK) present in HSV-1, HSV-2, and VZV-infected cells — viral TK converts acyclovir to acyclovir monophosphate far more efficiently than cellular kinases, creating a concentration gradient of roughly 40–100-fold in infected versus uninfected cells. Cellular kinases then complete the conversion to acyclovir triphosphate, which inhibits viral DNA polymerase and causes obligate chain termination after incorporation into the growing viral DNA strand.

The clinical spectrum of acyclovir encompasses HSV-1, HSV-2, and VZV. HSV-1 and HSV-2 are the most susceptible; VZV is approximately 10-fold less susceptible, requiring higher drug exposures — reflected in the substantially higher acyclovir doses used for varicella and zoster compared with HSV disease. EBV carries a viral TK of low activity and acyclovir has minimal clinically meaningful effect on EBV disease. CMV lacks a viral TK entirely and is intrinsically resistant to acyclovir. Oral bioavailability of acyclovir is poor (15–30%) and saturable at higher doses. Valacyclovir, the L-valyl ester prodrug of acyclovir, is rapidly hydrolyzed after oral administration to acyclovir, achieving plasma concentrations three to five times higher than equivalent oral acyclovir doses and approximating those achieved with intravenous acyclovir at standard doses. Acyclovir distributes widely, achieving therapeutic concentrations in cerebrospinal fluid (CSF) at approximately 50% of plasma levels — critical for treatment of herpes simplex encephalitis (HSE). Renal excretion is the primary elimination route; dose adjustment is required for creatinine clearance (CrCl) below 50 mL/min. Intravenous acyclovir can precipitate in renal tubules if infused rapidly or in hypovolemic patients — adequate hydration during intravenous infusion is essential.

Resistance to acyclovir in clinical practice is caused predominantly by mutations in the viral TK gene that reduce TK activity or alter substrate specificity so that acyclovir is no longer efficiently phosphorylated. TK-null and TK-partial mutants occur almost exclusively in immunocompromised patients receiving prolonged acyclovir therapy. Because TK is required for acyclovir activation but not for foscarnet or cidofovir activity, acyclovir-resistant HSV strains retain full susceptibility to both foscarnet and cidofovir — providing a clear therapeutic escape route. Less commonly, mutations in the viral DNA polymerase reduce acyclovir binding affinity and may confer partial cross-resistance to foscarnet.

Cidofovir and brincidofovir occupy a distinct niche in herpesvirus pharmacology, offering broad-spectrum DNA virus coverage extending well beyond the herpesvirus family. Cidofovir's clinical utility is severely limited by nephrotoxicity; brincidofovir uses lipid conjugate chemistry to deliver cidofovir's active metabolite intracellularly while bypassing the renal tubular accumulation that drives toxicity.

Cidofovir is an acyclic nucleoside phosphonate. Its pharmacological uniqueness is that it does not require viral TK or CMV UL97 for initial phosphorylation — cellular enzymes convert cidofovir directly to cidofovir diphosphate, the active moiety, which inhibits viral DNA polymerase causing chain termination after incorporation. Because activation is entirely virus-independent, cidofovir retains full activity against TK-deficient acyclovir-resistant HSV strains and against UL97-mutant ganciclovir-resistant CMV strains, provided the viral DNA polymerase remains susceptible. The antiviral spectrum is broad: CMV, HSV-1, HSV-2, VZV, adenovirus, BK polyomavirus (BKPyV), and orthopoxviruses including smallpox and mpox.

The clinical utility of cidofovir is severely constrained by dose-dependent nephrotoxicity. Cidofovir is concentrated in proximal tubular cells, reaching concentrations that cause mitochondrial dysfunction, tubular apoptosis, and progressive renal failure. The mandatory co-administration of probenecid substantially reduces cidofovir uptake into proximal tubular cells: probenecid 2 g is given orally three hours before each cidofovir dose and 1 g at two and eight hours after infusion. Aggressive intravenous saline pre-loading before each infusion is also required. Despite these precautions, serum creatinine must be checked before every dose, and cidofovir must be withheld if creatinine rises by 0.3 mg/dL or more above baseline or if proteinuria reaches 2+ or greater on dipstick. Uveitis and ocular hypotony are distinctive adverse effects reported primarily in HIV patients receiving systemic cidofovir.

Brincidofovir (CMX001) is a lipid conjugate of cidofovir linked via an ether lipid to improve oral bioavailability and reduce renal tubular uptake. The lipid conjugate enters cells via lipid transport pathways, dramatically reducing proximal tubular exposure and the associated nephrotoxicity. Brincidofovir received Food and Drug Administration (FDA) approval in 2021 for treatment of smallpox (variola virus) and has been used in mpox outbreaks. The primary adverse effects are gastrointestinal: diarrhea, nausea, vomiting, and abdominal pain can be treatment-limiting. Hepatotoxicity requires monitoring. The absence of significant nephrotoxicity compared with cidofovir makes brincidofovir potentially attractive for immunocompromised patients with renal insufficiency.

CMV disease in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, and in HIV patients with advanced immunodeficiency, requires individualized decisions about prophylaxis strategy, viral load monitoring thresholds, treatment intensity, and duration of secondary prophylaxis based on the patient's evolving immune status.

In solid organ transplantation, the risk of CMV disease is determined primarily by the donor and recipient CMV serostatus. The highest-risk combination is a CMV-seropositive donor organ transplanted into a CMV-seronegative recipient (D+/R-), carrying a 50–80% risk of CMV infection without prophylaxis. Two prophylaxis strategies have been validated: universal prophylaxis (valganciclovir or ganciclovir for a defined period post-transplant, typically 3–6 months) and pre-emptive therapy (monitoring CMV viral load by PCR and initiating therapy when viral load exceeds a predefined threshold before symptoms develop). Universal prophylaxis reduces CMV disease incidence more consistently but is associated with late-onset CMV disease occurring after prophylaxis discontinuation, particularly in D+/R- recipients. Letermovir, a CMV terminase inhibitor, is approved for prophylaxis in CMV-seropositive HSCT recipients from day 0 through day 100 post-transplant. Letermovir has no myelosuppressive activity — a major clinical advantage in HSCT recipients already at risk for prolonged neutropenia following conditioning. It is a moderate inhibitor of cytochrome P450 3A4 (CYP3A4) and increases tacrolimus and cyclosporine concentrations by 40–45% and 15% respectively, requiring dose reduction at initiation with frequent trough level monitoring.

CMV end-organ disease encompasses pneumonitis, gastrointestinal disease (esophagitis, colitis), hepatitis, retinitis, and neurological disease. CMV colitis presents with profuse watery or bloody diarrhea in immunocompromised patients; diagnosis requires colonoscopy with biopsy because blood CMV PCR is frequently negative or low-level in isolated gastrointestinal disease — the virus replicates locally without generating detectable systemic viremia in many cases. CMV pneumonitis in HSCT recipients carries the highest mortality, with rates of 30–50% despite antiviral therapy; treatment combines intravenous ganciclovir with intravenous immunoglobulin (IVIG). CMV retinitis in HIV patients with cluster of differentiation 4 (CD4) counts below 50 cells/µL is treated with valganciclovir 900 mg twice daily for induction followed by 900 mg once daily for maintenance; intravitreal ganciclovir or foscarnet injections are used as adjunctive therapy for immediately sight-threatening lesions.

CMV antiviral resistance should be suspected when quantitative CMV viral load fails to decline by at least one log10 copies/mL after two weeks of adequate ganciclovir therapy, or when CMV disease progresses despite treatment. Resistance is confirmed by genotypic testing of the UL97 and UL54 genes. UL97 mutations confer ganciclovir resistance by impairing drug phosphorylation; these strains typically retain foscarnet and cidofovir susceptibility. UL54 mutations may produce cross-resistance between ganciclovir, foscarnet, and cidofovir depending on the specific mutation; combined UL97 and UL54 mutations produce high-level multidrug resistance. Management of UL97-only resistance: switch to foscarnet. UL54 mutations with foscarnet cross-resistance: cidofovir may retain activity. Combined resistance: combination foscarnet plus ganciclovir at reduced doses, reduction of immunosuppression, and consideration of maribavir, which targets the UL97 kinase with a distinct mechanism and retains activity against most UL97 resistance mutations.